{"id":"NCT01078753","sponsor":"Ferring Pharmaceuticals","briefTitle":"Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis","officialTitle":"A Double-blind, Placebo-controlled, Phase III Comparative Study With FE992026 in Children and Adolescents With Reduced Night-time Urinary Osmolarity-type Nocturnal Enuresis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2010-09","completion":"2010-09","firstPosted":"2010-03-02","resultsPosted":"2011-11-02","lastUpdate":"2011-11-02"},"enrollment":89,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Nocturnal Enuresis"],"interventions":[{"type":"DRUG","name":"Desmopressin","otherNames":["FE992026","desmopressin melt","Minirin"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Desmopressin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is multi-center, randomized, placebo-controlled, parallel-group, double-blind, dose-escalating clinical trial designed to assess the efficacy and safety of desmopressin orally lyophilisate for the treatment of nocturnal enuresis \"with decreased nighttime urinary osmolality.\"","primaryOutcome":{"measure":"Change in the Number of Wet Nights Between Baseline and Treatment Period II","timeFrame":"Baseline (14-day period prior to starting study treatment) and Treatment Period II (weeks 3-4 after treatment initiation).","effectByArm":[{"arm":"Desmopressin","deltaMin":3.264,"sd":null},{"arm":"Placebo","deltaMin":1.451,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.009"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":9},"locations":{"siteCount":15,"countries":["Japan"]},"refs":{"pmids":["40728007"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":45},"commonTop":["Nasopharyngitis","Stomatitis","Asthenia","Empyema","Tonsillitis"]}}